Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Anti-seizure drugs could cause canine obesity, study finds
Dogs receiving ASD medication had a higher interest in food than healthy dogs.
Dogs taking the medication are more likely to have increased appetite.

New research has revealed that anti-seizure drugs (ASD) could be leading to more epileptic dogs becoming obese.

Researchers say that the drugs cause epileptic dogs to have an increased appetite which, when not properly managed, can cause weight issues. This risk is increased when dogs are given treats to help administer medication.

Dogs which suffer from idiopathic epilepsy are often prescribed ASD throughout their lifetimes. These drugs reduce the frequency and severity of the dog’s seizures, but rarely lead to seizure freedom.

The medication has a number of long-lasting side effects, including decreased energy, increased food intake and weight gain.

Though these side effects are widely published in veterinary literature, they have not previously been quantified or studied.

To analyse food motivation, researchers from the Royal Veterinary College (RVC) collaborated with the University of Cambridge to issue a validated Dog Obesity Risk Assessment questionnaire. The survey was designed to determine the link between ASDs and weight gain, as well as considering how caregivers manage weight gain.

The data compared 222 dogs that were diagnosed with idiopathic epilepsy with a control population of 7,086 healthy dogs.

Dogs which had idiopathic epilepsy and were receiving ASD were found to have a much higher food motivation than healthy dogs. They had increased interest in food, were less selective and were more interested in getting more food outside of meals.

Although their carers put effort into managing their pet’s diet, these dogs still had greater fat mass.

Fifty-three per cent of owners of dogs with epilepsy said they would always use treats to administer ASD medication, with 34 per cent saying they did not adjust their dog’s main food ration to suit. Since medication is usually administered twice a day, this can have a significant increase on calorie intake.

Rowena Packer, principal investigator of this research, said: “The findings of this research are key in helping the veterinary team provide greater information and support to pet owners managing their dog’s epilepsy.

“Although anti-seizure drugs are an essential part of the epilepsy treatment toolkit, ensuring owners are aware of the side effects and long-lasting impact of these medications is key in treatment decision-making, ensuring a balance between negative side effects such as increased food motivation against potential positive effects such as reduced seizure frequency, to maintain quality of life.”

The full study can be found in the journal Vet Record.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Webinar to explore AMR in vet dentistry

News Story 1
 The WSAVA has invited veterinary professionals to a webinar on responsible antibiotic usage in dentistry.

On 19 November 2025, at 1am, Dr J Scott Weese and Dr Brooke Niemiec will share the latest advice for antimicrobial use. They will present research on oral bacterology, and explain how attendees can choose appropriate antibiotics.

The session will cover pre-, intra- and post-operative guidelines, with recommendations for various pathologies.

The webinar is designed to support veterinary professionals to make informed decisions and tackle antimicrobial resistance.

Attendees can register here

Click here for more...
News Shorts
Bluetongue reaches Wales for first time in 2025

The Animal and Plant Health Agency (APHA) has revealed that bluetongue has been confirmed in Wales for the first time in 2025.

In their latest statistics, APHA records a total of 109 cases of BTV-3 or BTV-8 in Great Britain in the 2025-2026 vector season.

The total number of BTV-3 cases in Great Britain this season is 107. This includes 103 cases within the England restricted zone and four cases in Wales.

There has also been two cases of BTV-8, which were both in Cornwall.

As a result of the cases in Wales, a Temporary Control Zone (TCZ) is enforced in Monmouthshire. Animals can move freely under general license within the England Restricted Zone, however animals with suspected bluetongue must stay on their holding.

All premises testing positive for blue tongue can be viewed on this map.